These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 21129610)

  • 1. Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Silvestris N; Maiello E; De Vita F; Cinieri S; Santini D; Russo A; Tommasi S; Azzariti A; Numico G; Pisconti S; Petriella D; Lorusso V; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S46-55. PubMed ID: 21129610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Van Cutsem E; Verslype C; Tejpar S
    Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

  • 5. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    Cartwright T; McCollum D; Boehm KA
    Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Landherr L; Nagykálnai T
    Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metastatic colorectal cancer: adjournments from ESMO 2006].
    Bonetti A; Cascinu S; Falcone A; Maiello E; Zaniboni A; Aschele C
    Tumori; 2006; 92(6):1-12. PubMed ID: 17262903
    [No Abstract]   [Full Text] [Related]  

  • 9. Adjuvant therapy for stage II and III colorectal cancer.
    de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E
    Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
    [No Abstract]   [Full Text] [Related]  

  • 11. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 12. [Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Doi T; Ohtsu A
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():368-73. PubMed ID: 14574915
    [No Abstract]   [Full Text] [Related]  

  • 13. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Hurwitz H; Kabbinavar F
    Oncology; 2005; 69 Suppl 3():17-24. PubMed ID: 16301832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N; Heinemann V
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
    J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Booth C
    J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine: a review.
    Walko CM; Lindley C
    Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New therapy options in colorectal carcinoma].
    Folprecht G; Köhne CH
    Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.